Literature DB >> 6799483

Antibacterial activity of the monobactam SQ 26,776 against antibiotic resistant enterobacteria, including Serratia spp.

D S Reeves, M J Bywater, H A Holt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6799483     DOI： 10.1093/jac/8.suppl_e.57

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  8 in total

1.  Comparison of the effects of aztreonam and tigemonam against Escherichia coli and Klebsiella pneumoniae in vitro and in vivo.

Authors:  M L van Ogtrop; H Mattie; H F Guiot; E van Strijen; B R Sekh; R van Furth
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  In vitro activity of ciprofloxacin, azthreonam and ceftazidime against Serratia marcescens and Pseudomonas aeruginosa.

Authors:  J Righter
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

3.  In vitro antimicrobial activity of aztreonam alone and in combination against bacterial isolates from pediatric patients.

Authors:  H R Stutman; D F Welch; R K Scribner; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

Review 4.  Antibacterial therapy in patients with malignancies.

Authors:  K H Mayer; S M Opal
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 5.  Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R C Heel
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

6.  Evaluation of aztreonam in experimental bacterial meningitis and cerebritis.

Authors:  W M Scheld; J P Brodeur; J C Gratz; P Foresman; G Rodeheaver
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

7.  In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis.

Authors:  S C Aronoff; J D Klinger
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

8.  Pharmacokinetics of aztreonam in patients with chronic renal failure.

Authors:  J P Fillastre; A Leroy; C Baudoin; G Humbert; E A Swabb; C Vertucci; M Godin
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.